ImmunoGen Inc (IMGN)

US45253H1014 - Common Stock

31.23  0 (0%)

After market: 31.24 +0.01 (+0.03%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ImmunoGen Inc

NASDAQ:IMGN (2/9/2024, 7:00:02 PM)

After market: 31.24 +0.01 (+0.03%)

31.23

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.72B
Shares
PEN/A
Fwd PE81.49
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IMGN Daily chart

Company Profile

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. The company is headquartered in Waltham, Massachusetts and currently employs 277 full-time employees. The firm is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The firm is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Company Info

ImmunoGen Inc

830 Winter Street

Waltham MASSACHUSETTS 02451

P: 17818950600

CEO: Mark J. Enyedy

Employees: 277

Website: https://www.immunogen.com/

IMGN News

News Image19 days ago - InvestorPlace3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024

Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.

News Imagea month ago - BloombergAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel

Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings.

News Imagea month ago - BloombergAbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.

News Image2 months ago - Seeking AlphaAbbVie revises Q1 earnings outlook as ImmunoGen deal closes (NYSE:ABBV)

AbbVie updates its earnings outlook for Q1 2024, reflecting a dilutive impact from the completed acquisition of ImmunoGen.

News Image2 months ago - AbbVieAbbVie Completes Acquisition of ImmunoGen

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian...

News Image2 months ago - Investor's Business DailyAmicus Therapeutics Stock Sees Improved Relative Strength Rating

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

IMGN Twits

Here you can normally see the latest stock twits on IMGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example